Unfolding Securities Investigation Involving Tvardi Therapeutics
The cloud of uncertainty is swirling around Tvardi Therapeutics, Inc. (NASDAQ: TVRD) as investors find themselves potentially affected by serious allegations. A recent announcement from a prominent law firm specializing in shareholder rights has shed light on an investigation concerning possible securities law violations by the company.
Understanding the Investigation's Context
The investigation stems from claims that Tvardi may have issued misleading statements or failed to disclose essential details that could impact investors’ decisions. This has raised alarms among shareholders and potential investors alike, as the integrity of the company's communications is under scrutiny.
Recent Press Release and Its Impact
On October 13, 2025, Tvardi Therapeutics provided an update regarding its Phase 2 REVERT Trial in addressing Idiopathic Pulmonary Fibrosis. In what can only be categorized as a sobering revelation, the results indicated that the trial, which was subjected to rigorous standards, did not meet its intended goals. This information sparked a dramatic decline in the company’s stock price, diminishing by nearly 84% on that day alone.
What Led to the Sharp Decline?
Reports suggest that the REVERT trial was designed to evaluate the efficacy of TTI-101, either alone or in combination with nintedanib, a well-known treatment for pulmonary fibrosis. The trial’s failure to produce positive results is not just a setback for Tvardi but also raises questions about the company’s future and its communication to shareholders.
What Should Shareholders Do Now?
If you own shares of Tvardi and have experienced a financial loss, it is advisable to stay informed about this investigation. Engaging with legal experts who specialize in securities class action suits can provide clarity on potential steps to take.
The Role of Schall Law Firm
The Schall Law Firm is at the forefront of this investigation. They are actively encouraging impacted shareholders to discuss their circumstances without any cost. Their expertise could be invaluable in navigating the complex landscape of securities litigation.
How the Investigation Affects Future Investors
For those considering investing in Tvardi Therapeutics, understanding the ramifications of this investigation is critical. The potential for further declines in stock performance and the company's ability to rebound could be affected by the outcomes of these legal proceedings.
Contact Information for Legal Support
Should you wish to engage with legal representation regarding this matter, you can reach out to Brian Schall of the Schall Law Firm located at 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, or by calling 310-301-3335. Their knowledgeable staff is prepared to answer your questions free of charge, helping you understand your rights and options in this uncertain time.
Frequently Asked Questions
What is the current status of the investigation involving Tvardi Therapeutics?
The investigation focuses on potential violations of securities laws related to misleading statements made by the company.
How have shares of Tvardi Therapeutics been affected by recent news?
Shares plummeted almost 84% following the announcement of the unsuccessful results from the REVERT trial.
What should I do if I am a shareholder of Tvardi and suffered a loss?
It is recommended to consult with legal professionals to explore your options and understand your rights as an investor.
Who is leading the investigation into Tvardi Therapeutics?
The Schall Law Firm is leading the investigation and is offering to support shareholders impacted by the company's disclosures.
What can investors expect moving forward?
The outcome of the investigation may influence stock performance and the company's future, making it essential for investors to keep informed.
